By designing proteins de novo scientists can more efficiently create novel therapeutics tailored for specific biological ...

In addition to being faster and less invasive than a traditional tissue biopsy, the blood test is also potentially more accurate.

Chrysalis partners with life science clients, from early-stage biofirms to pharmaceutical firms, CROs, and other life science ...

A Roots Analysis study showed the market for ADC manufacturing is $1.79 billion today, but is expected to grow to $7 billion ...

GEN ranks not only the top 10 publicly traded developed of editing-based therapies, but the top five privately held companies ...

Nanoneedle tech could enable disease monitoring in real time, allowing clinicians to take multiple, repeatable tests from the ...

PRDX6 and GSTP1 identified as promising enzyme targets for neuroblastoma, offering an alternative to retinoic acid differentiation therapy.

PepGen leverages a graph-based approach to improve the detection of hidden protein variants in a computationally efficient manner.